AI Article Synopsis
- - MSC-based ATMPs are being explored for various clinical uses, highlighting their potential in regenerative medicine.
- - These cells can be sourced from multiple donor tissues or created from stem cells, but differences in production may affect their effectiveness and consistency.
- - The review emphasizes the importance of setting standardized manufacturing criteria for MSCs to enhance their reliability in clinical trials and therapeutic applications.
Article Abstract
Mesenchymal stromal cell (MSC)-based advanced therapy medicinal products (ATMPs) are being tried in a vast range of clinical applications. These cells can be isolated from different donor tissues by using several methods, or they can even be derived from induced pluripotent stem cells or embryonic stem cells. However, ATMP heterogeneity may impact product identity and potency, and, consequently, clinical trial outcomes. In this review, we discuss these topics and the need to establish minimal criteria regarding the manufacturing of MSCs so that these innovative therapeutics may be better positioned to contribute to the advancement of regenerative medicine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11173248 | PMC |
| http://dx.doi.org/10.3390/ijms25116063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!